For healthcare professionals only
Hosting partner:
diabetes on the net

This promotional website has been developed, organised and funded by Boehringer Ingelheim.​

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.

Webinar resources

Dr Sarah Jarvis, General Practitioner and Medical Broadcaster, London

Chair of the T2 Discussions webinar series alongside several experts

How to identify and support Diabetes Distress in adults with type 2 diabetes, and why it matters

Dr Sarah Jarvis & Professor Richard Holt

  • VIDEO
  • 39 min

Click here to view video

How to identify and support Diabetes Distress in adults with type 2 diabetes, and why it matters

  • Understand the definition, characteristic symptoms and impact of diabetes distress in adults with type 2 diabetes
  • Examine best practice for detecting and measuring diabetes distress
  • Discuss strategies to help support your patients with diabetes distress
  • VIDEO (SHORT)
  • 5 min

CLICK HERE TO VIEW SUMMARY VIDEO

  • Downloadable document

Click here to download

How to achieve treatment targets in adult type 2 diabetes and why is clinical inertia still an issue?

Dr Sarah Jarvis & Dr Kevin Fernando

  • VIDEO
  • 35 min

Click here to view video

How to achieve treatment targets in adult type 2 diabetes and why is clinical inertia still an issue?

  • Best practice for achieving treatment targets in adults with type 2 diabetes, including how frequently treatment targets should be assessed and key findings from the National Diabetes Audit
  • Practical tips for addressing clinical inertia with our patients
  • The importance of individualising treatment targets and the implications this may have for choice of pharmacotherapy
  • VIDEO (SHORT)
  • 15 min

CLICK HERE TO VIEW SUMMARY VIDEO

  • Downloadable document

Click here to download

How and when to switch or add in medications in adult type 2 diabetes

Dr Sarah Jarvis & Philip Newland-Jones

  • VIDEO
  • 45 min

Click here to view video

Switching and adding in medications in adult type 2 diabetes

  • Examining the evidence for adding in or switching medications in type 2 diabetes
  • A case-based overview of the when, why and how of adding in or switching medications
  • Considerations following a type 2 diabetes medication review
  • VIDEO (SHORT)
  • 10 min

CLICK HERE TO VIEW SUMMARY VIDEO

  • Downloadable document

Click here to download

  • Leaving soon

Hypoglycaemia in adult type 2 diabetes

Dr Sarah Jarvis & Su Down

  • VIDEO
  • 35 min

Click here to view video

Managing hypoglycaemia in type 2 diabetes

  • Hypoglycaemia: Definition, burden and impact
  • Tips for engaging in conversation to improve patient outcomes – The patient and clinician barriers and how to handle them
  • Resources for discussing hypoglycaemia with type 2 diabetes patients
  • Downloadable document

Click here to download

  • Webinar

Sarah Jarvis
Webinar Series Chair

To view the most recent webinar

Click here
  • VIRTUAL WEBINARS

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].

PC-GB-107170 V8 | March 2024

PC-GB-109919 | April 2024

Prescribing information for Great Britain and Northern Ireland and the Republic of Ireland 

This website is for healthcare professionals in Great Britain, Northern Ireland and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in Great Britain, Northern Ireland or the Republic of Ireland by clicking below.
I am
I am not
Prescribing information for Great Britain and Northern Ireland
Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].


You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

OK
Cancel